Sangamo Therapeutics (NASDAQ:SGMO) Receives “Buy” Rating from HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.

SGMO has been the topic of a number of other research reports. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Wall Street Zen raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

Sangamo Therapeutics Price Performance

SGMO stock opened at $0.55 on Thursday. Sangamo Therapeutics has a 1-year low of $0.41 and a 1-year high of $3.18. The business has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.64. The company has a market capitalization of $165.10 million, a P/E ratio of -1.89 and a beta of 1.20.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. The company had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $31.68 million. On average, analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 21,793 shares during the period. R Squared Ltd purchased a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $28,000. Captrust Financial Advisors purchased a new position in shares of Sangamo Therapeutics during the fourth quarter worth approximately $30,000. Cerity Partners LLC grew its position in shares of Sangamo Therapeutics by 439.2% during the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 44,800 shares during the last quarter. Finally, Caption Management LLC acquired a new position in Sangamo Therapeutics in the 1st quarter valued at about $37,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.